Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
NEWARK, Calif., May 04, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, May 11th at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2017 and provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13661044. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional Information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
